Efficacy and prognostic analysis of relapsed/refractory diffuse large B-cell lymphoma patients with hepatitis B virus infection.
10.3760/cma.j.issn.0253-2727.2018.12.009
- VernacularTitle:乙型肝炎病毒感染对复发难治性弥漫大B细胞淋巴瘤疗效及预后的影响
- Author:
Ying FANG
1
,
2
;
Li WANG
;
Ying QIAN
;
Wei Li ZHAO
Author Information
1. State Key Laboratory of Medical Genomics
2. Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai 200025, China.
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Lymphoma, large B-cell, diffuse;
Recurrence;
Refractory
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Hepatitis B/complications*;
Hepatitis B virus;
Humans;
Lymphoma, Large B-Cell, Diffuse/complications*;
Neoplasm Recurrence, Local;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Hematology
2018;39(12):1017-1020
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the clinical and prognostic significance of hepatitis B virus infection on patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Methods: A retrospective analysis was performed in 81 relapsed/refractory DLBCL cases who were treated with salvage regimens from January 2004 to November 2016. The patients were divided into two group, HBsAg positive and HBsAg negative group, and assessed the clinical features and survival time of two groups. Results: Twenty-four (29.6%) patients were HBsAg positive and 57(70.4%) were negative. HBsAg-positive DLBCL patients showed unique clinical features, including more younger patients (P=0.005), more advanced Ann Arbor stage (P<0.001), high-risk IPI (P=0.010), more hypohemoglobin (P=0.015), especially extra-nodal involvement (P=0.038) and recurrence (P=0.002). Overall response rate (29.2% vs 68.4%, χ(2)=10.720, P=0.001) and median overall survival time [(11.3±2.9) months vs (30.0±7.6) months, χ(2)=28.175, P<0.001] were inferior in HBsAg-positive patients, respectively. Conclusion: To strictly control HBV infection plays an important role on the survival and prognosis of relapsed/refractory lymphoma patients.
